Ketogenic diet does not promote triple-negative and luminal mammary tumor growth and metastasis in experimental mice.
Breast cancer
Ketogenic diet
Ketosis
Metastasis
Primary tumor growth
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
09 Dec 2023
09 Dec 2023
Historique:
received:
17
10
2023
accepted:
21
11
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
8
12
2023
Statut:
aheadofprint
Résumé
Ketogenic diets (KDs) can improve the well-being and quality of life of breast cancer patients. However, data on the effects of KDs on mammary tumors are inconclusive, and the influence of KDs on metastasis in general remains to be investigated. We therefore assessed the impact of a KD on growth and metastasis of triple negative murine 4T1 mammary tumors, and on the progression of luminal breast tumors in an autochthonous MMTV-PyMT mouse model. We found that KD did not influence the metastasis of 4T1 and MMTV-PyMT mammary tumors, but impaired 4T1 tumor cell proliferation in vivo, and also temporarily reduced 4T1 primary tumor growth. Notably, the ketogenic ratio (the mass of dietary fat in relation to the mass of dietary carbohydrates and protein) that is needed to induce robust ketosis was twice as high in mice as compared to humans. Surprisingly, only female but not male mice responded to KD with a sustained increase in blood β-hydroxybutyrate levels. Together, our data show that ketosis does not foster primary tumor growth and metastasis, suggesting that KDs can be safely applied in the context of luminal breast cancer, and may even be advantageous for patients with triple negative tumors. Furthermore, our data indicate that when performing experiments with KDs in mice, the ketogenic ratio needed to induce ketosis must be verified, and the sex of the mice should also be taken into account.
Identifiants
pubmed: 38066243
doi: 10.1007/s10585-023-10249-z
pii: 10.1007/s10585-023-10249-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Gesellschaft für Neuropädiatrie e.V. (GNP) (2023): S1-Leitlinie Ketogene Diäten, 4.1, 30.11.2021. https://register.awmf.org/de/leitlinien/detail/022-021 . Accessed 16 Oct 2023
Flowers L, Broder MW, Forsyth C (2003) Toxicological review of acetone (CAS No. 67-64-1). In Support of summary information on the integrated risk information system (IRIS). U.S. Environmental Protection Agency Washington, DC. EPA/635/R-03/004 https://www.epa.gov/iri
Glew RH (2010) You can get there from here: acetone, anionic ketones and even-carbon fatty acids can provide substrates for gluconeogenesis. Niger J Physiol Sci 25:2–4
pubmed: 22314896
Kossoff EH, Wang HS (2013) Dietary therapies for epilepsy. Biomed J 36:2–8. https://doi.org/10.4103/2319-4170.107152
doi: 10.4103/2319-4170.107152
pubmed: 23515147
Fearon KC, Borland W, Preston T, Tisdale MJ, Shenkin A, Calman KC (1988) Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr 47:42e48
doi: 10.1093/ajcn/47.1.42
Klement RJ, Sweeney RA (2016) Impact of a ketogenic diet intervention during radiotherapy on body composition: II. Protocol of a randomised phase I study (KETOCOMP). Clin Nutr ESPEN 12:e1–e6. https://doi.org/10.1016/j.clnesp.2015.11.001
doi: 10.1016/j.clnesp.2015.11.001
pubmed: 28531663
Kämmerer U, Klement RJ, Joos FT, Sütterlin M, Reuss-Borst M (2021) Low Carb and ketogenic diets increase quality of life, physical performance, body composition, and metabolic health of women with breast cancer. Nutrients 13:1029. https://doi.org/10.3390/nu13031029
doi: 10.3390/nu13031029
pubmed: 33806775
pmcid: 8004887
Klement RJ, Sweeney RA (2022) Impact of a ketogenic diet intervention during radiotherapy on body composition: V. final results of the KETOCOMP study for head and neck cancer patients. Strahlenther Onkol 198:981–993. https://doi.org/10.1007/s00066-022-01941-2
doi: 10.1007/s00066-022-01941-2
pubmed: 35499696
pmcid: 9059453
Nebeling LC, Miraldi F, Shurin SB, Lerner E (1995) Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 14:202–208. https://doi.org/10.1080/07315724.1995.10718495
doi: 10.1080/07315724.1995.10718495
pubmed: 7790697
Schmidt M, Pfetzer N, Schwab M, Strauss I, Kämmerer U (2011) Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr Metab 8:54. https://doi.org/10.1186/1743-7075-8-54
doi: 10.1186/1743-7075-8-54
Cohen CW, Fontaine KR, Arend RC, Soleymani T, Gower BA (2018) Favorable effects of a ketogenic diet on physical function, perceived energy, and food cravings in women with ovarian or endometrial cancer: a randomized, controlled trial. Nutrients 10:1187. https://doi.org/10.3390/nu10091187
doi: 10.3390/nu10091187
pubmed: 30200193
pmcid: 6163837
Klement RJ (2017) Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation. Med Oncol 34:132. https://doi.org/10.1007/s12032-017-0991-5
doi: 10.1007/s12032-017-0991-5
pubmed: 28653283
Klement RJ (2018) Wilhelm Brünings’ forgotten contribution to the metabolic treatment of cancer utilizing hypoglycemia and a very low carbohydrate (ketogenic) diet. J Tradit Complement Med 9:192–200. https://doi.org/10.1016/j.jtcme.2018.06.002
doi: 10.1016/j.jtcme.2018.06.002
pubmed: 31193891
pmcid: 6544614
Klement RJ, Brehm N, Sweeney RA (2020) Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes. Med Oncol 37:14. https://doi.org/10.1007/s12032-020-1337-2
doi: 10.1007/s12032-020-1337-2
pubmed: 31927631
Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP (2010) Ketones and lactate fuel tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9:3506–3514. https://doi.org/10.4161/cc.9.17.12731
doi: 10.4161/cc.9.17.12731
pubmed: 20818174
pmcid: 3047616
Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP (2012) Ketone body utilization drives Tumor growth and Metastasis. Cell Cycle 11:3964–3971. https://doi.org/10.4161/cc.22137
doi: 10.4161/cc.22137
pubmed: 23082722
pmcid: 3507492
Gluschnaider U, Hertz R, Ohayon S, Smeir E, Smets M, Pikarsky E, Bar-Tana J (2014) Long-chain fatty acid analogues suppress breast tumorigenesis and progression. Cancer Res 74:6991–7002. https://doi.org/10.1158/0008-5472.CAN-14-0385
doi: 10.1158/0008-5472.CAN-14-0385
pubmed: 25304261
Talib WH (2020) A ketogenic diet combined with melatonin overcomes cisplatin and vincristine drug resistance in breast carcinoma syngraft. Nutrition 72:110659. https://doi.org/10.1016/j.nut.2019.110659
doi: 10.1016/j.nut.2019.110659
pubmed: 31986320
Zou Y, Fineberg S, Pearlman A, Feinman RD, Fine EJ (2020) The effect of a ketogenic diet and synergy with rapamycin in a mouse model of Breast cancer. PLoS ONE 15:e0233662. https://doi.org/10.1371/journal.pone.0233662
doi: 10.1371/journal.pone.0233662
pubmed: 33270630
pmcid: 7714189
Wang X, Liu X, Jia Z, Zhang Y, Wang S, Zhang H (2021) Evaluation of the effects of different dietary patterns on breast cancer: monitoring circulating tumor cells. Foods 10:2223. https://doi.org/10.3390/foods10092223
doi: 10.3390/foods10092223
pubmed: 34574333
pmcid: 8465684
Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B (2020) Ketogenic diet in the treatment of cancer—where do we stand? Mol Metab 33:102–121. https://doi.org/10.1016/j.molmet.2019.06.026
doi: 10.1016/j.molmet.2019.06.026
pubmed: 31399389
Zuo Q, Mogol AN, Liu YJ, Santaliz Casiano A, Chien C, Drnevich J, Imir OB, Kulkoyluoglu-Cotul E, Park NH, Shapiro DJ, Park BH, Ziegler Y, Katzenellenbogen BS, Aranda E, O’Neill JD, Raghavendra AS, Tripathy D, Madak Erdogan Z (2022) Targeting metabolic adaptations in the breast cancer-liver metastatic niche using dietary approaches to improve endocrine therapy efficacy. Mol Cancer Res 20:923–937. https://doi.org/10.1158/1541-7786.MCR-21-0781
doi: 10.1158/1541-7786.MCR-21-0781
pubmed: 35259269
pmcid: 9177734
Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954–961. https://doi.org/10.1128/mcb.12.3.954-961.1992
doi: 10.1128/mcb.12.3.954-961.1992
pubmed: 1312220
pmcid: 369527
Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. https://doi.org/10.1016/S0002-9440(10)63568-7
doi: 10.1016/S0002-9440(10)63568-7
pubmed: 14578209
pmcid: 1892434
FELASA working group on revision of guidelines for health monitoring of rodents and rabbits, Mähler Convenor M, Berard M, Feinstein R, Gallagher A, Illgen-Wilcke B, Pritchett-Corning K, Raspa M (2014) FELASA recommendations for the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimental units. Lab Anim 48:178–192. https://doi.org/10.1177/0023677213516312
doi: 10.1177/0023677213516312
Klement RJ, Champ CE, Otto C, Kämmerer U (2016) Anti-tumor effects of ketogenic diets in mice: a meta-analysis. PLoS ONE 11:e0155050. https://doi.org/10.1371/journal.pone.0155050
doi: 10.1371/journal.pone.0155050
pubmed: 27159218
pmcid: 4861343
Dmitrieva-Posocco O, Wong AC, Lundgren P, Golos AM, Descamps HC, Dohnalová L, Cramer Z, Tian Y, Yueh B, Eskiocak O, Egervari G, Lan Y, Liu J, Fan J, Kim J, Madhu B, Schneider KM, Khoziainova S, Andreeva N, Wang Q, Li N, Furth EE, Bailis W, Kelsen JR, Hamilton KE, Kaestner KH, Berger SL, Epstein JA, Jain R, Li M, Beyaz S, Lengner CJ, Katona BW, Grivennikov SI, Thaiss CA, Levy M (2022) β-Hydroxybutyrate suppresses colorectal cancer. Nature 605:160–165. https://doi.org/10.1038/s41586-022-04649-6
doi: 10.1038/s41586-022-04649-6
pubmed: 35477756
pmcid: 9448510
Fine EJ, Segal-Isaacson CJ, Feinman RD, Herszkopf S, Romano MC, Tomuta N, Bontempo AF, Negassa A, Sparano JA (2012) Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition 28:1028–1035. https://doi.org/10.1016/j.nut.2012.05.001
doi: 10.1016/j.nut.2012.05.001
pubmed: 22840388
Branca JJ, Pacini S, Ruggiero M (2015) Effects of pre-surgical vitamin D supplementation and ketogenic diet in a patient with recurrent breast cancer. Anticancer Res 35:5525–5532
pubmed: 26408720
Jansen N, Walach H (2016) The development of tumours under a ketogenic diet in association with the novel tumour marker TKTL1: a case series in general practice. Oncol Lett 11:584–592. https://doi.org/10.3892/ol.2015.3923
doi: 10.3892/ol.2015.3923
pubmed: 26870251
Schwalb M, Taubmann M, Hines S, Reinwald H, Ruggiero M (2016) Clinical Observation of a Novel, complementary, immunotherapeutic Approach based on Ketogenic Diet, Chondroitin Sulfate, vitamin D3, oleic acid and a fermented milk and Colostrum product. Am J Immunol 12:91–98. https://doi.org/10.3844/ajisp.2016.91.98
doi: 10.3844/ajisp.2016.91.98
Khodabakhshi A, Akbari ME, Mirzaei HR, Mehrad-Majd H, Kalamian M, Davoodi SH (2020) Feasibility, Safety, and Beneficial effects of MCT-Based ketogenic Diet for Breast Cancer Treatment: a Randomized Controlled Trial Study. Nutr Cancer 72:627–634. https://doi.org/10.1080/01635581.2019.1650942
doi: 10.1080/01635581.2019.1650942
pubmed: 31496287
Khodabakhshi A, Seyfried TN, Kalamian M, Beheshti M, Davoodi SH (2020) Does a ketogenic diet have beneficial effects on quality of life, physical activity or biomarkers in patients with Breast cancer: a randomized controlled clinical trial. Nutr J 19:87. https://doi.org/10.1186/s12937-020-00596-y
doi: 10.1186/s12937-020-00596-y
pubmed: 32828130
pmcid: 7443288
Khodabakhshi A, Akbari ME, Mirzaei HR, Seyfried TN, Kalamian M, Davoodi SH (2021) Effects of ketogenic metabolic therapy on patients with Breast cancer: a randomized controlled clinical trial. Clin Nutr 40:751–758. https://doi.org/10.1016/j.clnu.2020.06.028
doi: 10.1016/j.clnu.2020.06.028
pubmed: 32703721
Rodrigues LM, Uribe-Lewis S, Madhu B, Honess DJ, Stubbs M, Griffiths JR (2017) The action of β-hydroxybutyrate on the growth, metabolism and global histone H3 acetylation of spontaneous mouse mammary tumours: evidence of a β-hydroxybutyrate paradox. Cancer Metab 5:4. https://doi.org/10.1186/s40170-017-0166-z
doi: 10.1186/s40170-017-0166-z
pubmed: 28261475
pmcid: 5331634
Zhuang Y, Chan DK, Haugrud AB, Miskimins WK (2014) Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. PLoS ONE 9:e108444. https://doi.org/10.1371/journal.pone.0108444
doi: 10.1371/journal.pone.0108444
pubmed: 25254953
pmcid: 4177919
Poff AM, Ward N, Seyfried TN, Arnold P, D’Agostino DP (2015) Non-toxic metabolic management of Metastatic Cancer in VM mice: Novel Combination of Ketogenic Diet, Ketone Supplementation, and hyperbaric oxygen therapy. PLoS ONE 10:e0127407. https://doi.org/10.1371/journal.pone.0127407
doi: 10.1371/journal.pone.0127407
pubmed: 26061868
pmcid: 4464523
Volek JS, Phinney SD (2012) The art and science of low carbohydrate performance. Beyond Obesity, LLC, Miami
Licha D, Vidali S, Aminzadeh-Gohari S, Alka O, Breitkreuz L, Kohlbacher O, Reischl RJ, Feichtinger RG, Kofler B, Huber CG (2019) Untargeted Metabolomics reveals Molecular effects of Ketogenic Diet on Healthy and Tumor Xenograft Mouse models. Int J Mol Sci 20:3873. https://doi.org/10.3390/ijms20163873
doi: 10.3390/ijms20163873
pubmed: 31398922
pmcid: 6719192
Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R, Voelker HU, Thiede A, Coy JF (2008) Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer 8:122. https://doi.org/10.1186/1471-2407-8-122
doi: 10.1186/1471-2407-8-122
pubmed: 18447912
pmcid: 2408928
Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, Scheck AC (2010) The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab 7:74. https://doi.org/10.1186/1743-7075-7-74
doi: 10.1186/1743-7075-7-74
Dang MT, Wehrli S, Dang CV, Curran T (2015) The ketogenic Diet does not affect growth of hedgehog pathway Medulloblastoma in mice. PLoS ONE 10:e0133633. https://doi.org/10.1371/journal.pone.0133633
doi: 10.1371/journal.pone.0133633
pubmed: 26192445
pmcid: 4507880
Dutton SB, Escayg A (2008) Genetic influences on ketogenic diet efficacy. Epilepsia 49:67–69. https://doi.org/10.1111/j.1528-1167.2008.01839.x
doi: 10.1111/j.1528-1167.2008.01839.x
pubmed: 19049592
pmcid: 2653419
Langer HT, Ramsamooj S, Liang RJ, Grover R, Hwang SK, Goncalves MD (2022) Systemic ketone replacement does not improve survival or Cancer Cachexia in mice with Lung Cancer. Front Oncol 12:903157. https://doi.org/10.3389/fonc.2022.903157
doi: 10.3389/fonc.2022.903157
pubmed: 35719965
pmcid: 9203842
Warburg O, Posener K, Negelein E (1924) Über den stoffwechsel der carcinomzelle. Biochem Z 152:309
Hao GW, Chen YS, He DM, Wang HY, Wu GH, Zhang B (2015) Growth of human colon Cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. Asian Pac J Cancer Prev 16:2061–2068. https://doi.org/10.7314/apjcp.2015.16.5.2061
doi: 10.7314/apjcp.2015.16.5.2061
pubmed: 25773851
Jain R, Li D, Gupta M, Manderfield LJ, Ifkovits JL, Wang Q, Liu F, Liu Y, Poleshko A, Padmanabhan A, Raum JC, Li L, Morrisey EE, Lu MM, Won KJ, Epstein JA (2015) Heart development. Integration of Bmp and wnt signaling by Hopx specifies commitment of cardiomyoblasts. Science 348:6071. https://doi.org/10.1126/science.aaa6071
doi: 10.1126/science.aaa6071
Palpant NJ, Wang Y, Hadland B, Zaunbrecher RJ, Redd M, Jones D, Pabon L, Jain R, Epstein J, Ruzzo WL, Zheng Y, Bernstein I, Margolin A, Murry CE (2017) Chromatin and Transcriptional Analysis of Mesoderm Progenitor Cells Identifies HOPX as a Regulator of primitive hematopoiesis. Cell Rep 20:1597–1608. https://doi.org/10.1016/j.celrep.2017.07.067
doi: 10.1016/j.celrep.2017.07.067
pubmed: 28813672
pmcid: 5576510
Liang H, Wang C, Gao K, Li J, Jia R (2019) ΜicroRNA-421 promotes the progression of nonsmall cell lung cancer by targeting HOPX and regulating the Wnt/βcatenin signaling pathway. Mol Med Rep 20:151–161. https://doi.org/10.3892/mmr.2019.10226
doi: 10.3892/mmr.2019.10226
pubmed: 31115507
pmcid: 6580023
Xu X, Zhang M, Xu F, Jiang S (2020) Wnt signaling in Breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer 19:165. https://doi.org/10.1186/s12943-020-01276-5
doi: 10.1186/s12943-020-01276-5
pubmed: 33234169
pmcid: 7686704
Buechel D, Sugiyama N, Rubinstein N, Saxena M, Kalathur RKR, Lüönd F, Vafaizadeh V, Valenta T, Hausmann G, Cantù C, Basler K, Christofori G (2021) Parsing β-catenin’s cell adhesion and wnt signaling functions in malignant mammary Tumor progression. Proc Natl Acad Sci USA 118:e2020227118. https://doi.org/10.1073/pnas.2020227118
doi: 10.1073/pnas.2020227118
pubmed: 34408016
pmcid: 8403962